- Oral presentation of results showed sustained improvements through Week 52, as well as safety and tolerability similar to that previously reported for the initial 26-week blinded portion of the Phase 3 PaTHway Trial - At Week 52, 95% of patients treated with TransCon PTH achieved independence from conventional therapy - TransCon PTH treatment improved mean patient-reported disease symptom and health-related quality of life scores, starting at the first scheduled follow up after randomization o